Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology innovations, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's management will engage in a fireside chat on Thursday, September 5, 2024, at 1:50 pm ET.
Interested parties can access the webcast through the 'Events' section of Arcutis' website. A replay of the presentation will remain available on the company's website for 180 days following the conference, providing extended access to investors and stakeholders unable to attend the live event.
Arcutis Biotherapeutics (Nasdaq: ARQT), una società biofarmaceutica in fase commerciale specializzata nelle innovazioni in immuno-dermatologia, ha annunciato la sua partecipazione alla 22ª Conferenza Globale della Salute di Morgan Stanley. La direzione dell'azienda parteciperà a un fireside chat giovedì 5 settembre 2024, alle 13:50 ET.
Le parti interessate possono accedere al webcast tramite la sezione 'Eventi' del sito web di Arcutis. Una registrazione della presentazione sarà disponibile sul sito dell'azienda per 180 giorni dopo la conferenza, offrendo un accesso prolungato agli investitori e agli stakeholder che non possono partecipare all'evento dal vivo.
Arcutis Biotherapeutics (Nasdaq: ARQT), una empresa biofarmacéutica en etapa comercial especializada en innovaciones en inmunodermatología, ha anunciado su participación en la 22ª Conferencia Global de Salud de Morgan Stanley. La dirección de la empresa participará en un fireside chat el jueves 5 de septiembre de 2024, a la 1:50 pm ET.
Las partes interesadas pueden acceder a la transmisión a través de la sección 'Eventos' en el sitio web de Arcutis. Una repetición de la presentación estará disponible en el sitio web de la empresa durante 180 días después de la conferencia, proporcionando acceso ampliado a inversores y partes interesadas que no puedan asistir al evento en vivo.
Arcutis Biotherapeutics (Nasdaq: ARQT), 면역 피부과 혁신에 특화된 상업 단계 생명공학 회사가 모건 스탠리 제22회 글로벌 헬스케어 콘퍼런스에 참가한다고 발표했습니다. 회사 경영진은 2024년 9월 5일 목요일 오후 1:50 ET에 파이어사이드 채팅에 참여할 것입니다.
관심 있는 관계자는 Arcutis 웹사이트의 '이벤트' 섹션을 통해 웹캐스트에 접속할 수 있습니다. 발표의 재생은 컨퍼런스 후 180일 동안 회사 웹사이트에서 제공되어, 실시간 이벤트에 참석할 수 없는 투자자와 이해관계자에게 연장된 접근을 제공합니다.
Arcutis Biotherapeutics (Nasdaq: ARQT), une entreprise biopharmaceutique en phase commerciale spécialisée dans les innovations en immunodermatologie, a annoncé sa participation à la 22ème Conférence Mondiale sur la Santé de Morgan Stanley. La direction de l'entreprise participera à un fireside chat le jeudi 5 septembre 2024, à 13h50 ET.
Les parties intéressées peuvent accéder à la diffusion en direct via la section 'Événements' du site web d'Arcutis. Un enregistrement de la présentation sera disponible sur le site de l'entreprise pendant 180 jours après la conférence, offrant un accès prolongé aux investisseurs et aux parties prenantes qui ne peuvent pas participer à l'événement en direct.
Arcutis Biotherapeutics (Nasdaq: ARQT), ein biopharmazeutisches Unternehmen in der Gewerbefase, das sich auf Innovationen in der Immundermatologie spezialisiert hat, hat seine Teilnahme an der 22. jährlichen globalen Healthcare-Konferenz von Morgan Stanley bekannt gegeben. Das Management des Unternehmens wird an einem Fireside-Chat am Donnerstag, den 5. September 2024, um 13:50 Uhr ET teilnehmen.
Interessierte Parteien können auf das Webcast über den Bereich 'Veranstaltungen' auf der Arcutis-Website zugreifen. Eine Wiederholung der Präsentation wird 180 Tage nach der Konferenz auf der Website des Unternehmens verfügbar sein und bietet langfristigen Zugang für Investoren und Interessengruppen, die nicht an der Live-Veranstaltung teilnehmen können.
- None.
- None.
WESTLAKE VILLAGE, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference.
Details for the company’s participation are as follows:
Fireside Chat Date: Thursday, September 5, 2024
Fireside Chat Time: 1:50 pm ET
The webcast for this conference may be accessed at the “Events” section of the Company’s website. A replay of the webcast will be available on the Arcutis website for 180 days following the conference.
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio including three FDA approved products that harness our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, and alopecia areata. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram and X.
Forward-Looking Statements
This press release contains “forward-looking” statements, including, among others, statements regarding its potential to address urgent needs and expectations with regard to the timing of data and regulatory events. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, the timing and expenses of commercialization efforts, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the “Risk Factors” section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 27, 2024, as well as any subsequent filings with the SEC. You should not place undue reliance on any forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com
Investors
Latha Vairavan, Vice President, Finance and Investor Relations
ir@arcutis.com
FAQ
When is Arcutis Biotherapeutics (ARQT) presenting at the Morgan Stanley Healthcare Conference?
How can I watch Arcutis Biotherapeutics' (ARQT) presentation at the Morgan Stanley conference?
How long will the replay of Arcutis Biotherapeutics' (ARQT) Morgan Stanley conference presentation be available?
What is the focus of Arcutis Biotherapeutics (ARQT) as a company?
